United States

Australia

Australia

Investor & Media Enquiries:

Investor Enquiries:

Media Enquiries:

REVA Medical, Inc.

Inteq Limited

Buchan Consulting

Cheryl Liberatore

Kim Jacobs

Rebecca Wilson

Director, Investor Relations

+61 2 9229 2700

+61 3 9866 4722

+1 858-966-3045

Annabel Murphy

+61 2 9237 2800

Name of entity

REVA Medical, Inc.

ARBN

146 505 777

1

+Class of +securities issued or to be issued

1) Issuance of convertible notes (unquoted).

2) Issuance of options (unquoted).

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

1) 250 convertible notes.

2) 8,750,000 options to purchase 8,750,000 shares of common stock (equivalent to 87,500,000 CDIs).

3

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Convertible notes and options issued under Convertible Note Deed.

1) 250 convertible notes with face value of US$100,000, the full terms of which were disclosed to the market on 16 October 2014.

2) 8,750,000 options exerciserable at any time into common stock for either (a) A$0.25 per share prior to full enrolment of REVA’s Fantom product in a CE clinical study, or, (b) A$0.30 per share thereafter. Options expire five years after issuance if not exercised. The full terms on which the options are being issued were disclosed to the market on 16 October 2014.

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No.

1) Convertible notes are not entitled to any rights of stockholders.

2) Options are not entitled to any rights of stockholders.

5

Issue price or consideration

1) Convertible notes for total consideration of US$25,000,000.

2) No monetary consideration is payable for the issuance of options.

6

Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Issuance of convertible notes to fund future operations of the Company.

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b — 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes.

6b

The date the security holder resolution under rule 7.1A was passed

13 May 2014.

6c

Number of +securities issued without security holder approval under rule 7.1

Not applicable.

6d

Number of +securities issued with security holder approval under rule 7.1A

Not applicable.

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

1) 250 convertible notes.

2) 8,750,000 options to purchase 8,750,000 shares of common stock (equivalent to 87,500,000 CDIs).

The meeting to approve the issue of the convertible notes and the options was held on 31 October 2014.

6f

Number of +securities issued under an exception in rule 7.2

Not applicable.

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

Not applicable.

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not applicable.

6i

Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements

Remaining capacity under Listing Rule 7.1: 5,029,467 shares of common stock (equivalent to 50,294,667 CDIs).

Remaining capacity under Listing Rule 7.1A: 3,352,978 shares of common stock (equivalent to 33,529,778 CDIs).

Please see Annexure 1 for further details.

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

Convertible notes and options issued 14 November 2014.

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

335,297,780 CDIs are quoted, assuming all shares of common stock are held as CDIs (a total of 33,529,778 common shares are issued and outstanding).

CDIs

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

794,925 options (over 794,925 shares of common stock or 7,949,250 CDIs).

Options issued under the 2001 Stock Option/Stock Issuance Plan.

3,448,500 options (over 3,448,500 shares of common stock or 34,485,000 CDIs).

Options issued under the Amended and Restated 2010 Equity Incentive Plan.

250 convertible notes.

Convertible notes issued under Convertible Note Deed dated 25 September 2014.

8,750,000 options (over 8,750,000 shares of common stock or 87,500,000 CDIs)

Options issued under Convertible Note Deed dated 25 September 2014.

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable.

11

Is security holder approval required?

Not applicable.

12

Is the issue renounceable or non-renounceable?

Not applicable.

13

Ratio in which the +securities will be offered

Not applicable.

14

+Class of +securities to which the offer relates

Not applicable.

15

+Record date to determine entitlements

Not applicable.

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

Not applicable.

17

Policy for deciding entitlements in relation to fractions

Not applicable.

18

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

Not applicable.

19

Closing date for receipt of acceptances or renunciations

Not applicable.

20

Names of any underwriters

Not applicable.

21

Amount of any underwriting fee or commission

Not applicable.

22

Names of any brokers to the issue

Not applicable.

23

Fee or commission payable to the broker to the issue

Not applicable.

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

Not applicable.

25

If the issue is contingent on security holders’ approval, the date of the meeting

Not applicable.

26

Date entitlement and acceptance form and offer documents will be sent to persons entitled

Not applicable.

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

Not applicable.

28

Date rights trading will begin (if applicable)

Not applicable.

29

Date rights trading will end (if applicable)

Not applicable.

30

How do security holders sell their entitlements in full through a broker?

Not applicable.

31

How do security holders sell part of their entitlements through a broker and accept for the balance?

Not applicable.

32

How do security holders dispose of their entitlements (except by sale through a broker)?

Not applicable.

33

+Issue date

Not applicable.

34

Type of +securities

(tick one)

(a)

o

+Securities described in Part 1

(b)

o

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

35

o

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36

o

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37

o

A copy of any trust deed for the additional +securities

38

Number of +securities for which +quotation is sought

Not applicable.

39

+Class of +securities for which quotation is sought

Not applicable.

40

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Not applicable.

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

Not applicable.

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Not applicable.

Not applicable.

Sign here:

/s/ Katrina L. Thompson

Date: 14 November 2014

(Company Secretary)

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

332,700,530 CDIs (assuming all shares of common stock were held as CDIs).

Add the following:

·                  Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

·                  Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

·                  Number of partly paid +ordinary securities that became fully paid in that 12 month period

Note:

·                  Include only ordinary securities here — other classes of equity securities cannot be added

·                  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

·                  It may be useful to set out issues of securities on different dates as separate line items

259,725 shares of common stock (equivalent to 2,597,250 CDIs).

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

Nil

“A”

335,297,780 CDIs (assuming all shares of common stock were held as CDIs).

“B”

0.15

Multiply “A” by 0.15

50,294,667 CDIs (assuming all shares of common stock were held as CDIs).

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

·                  Under an exception in rule 7.2

·                  Under rule 7.1A

·                  With security holder approval under rule 7.1 or rule 7.4

Note:

·                  This applies to equity securities, unless specifically excluded — not just ordinary securities

·                  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

·                  It may be useful to set out issues of securities on different dates as separate line items

Nil

“C”

Nil

“A” x 0.15

Note: number must be same as shown in Step 2

50,294,667 CDIs (assuming all shares of common stock were held as CDIs).

Subtract “C”

Note: number must be same as shown in Step 3

Nil

Total [“A” x 0.15] – “C”

50,294,667 CDIs (assuming all shares of common stock were held as CDIs).

Note: this is the remaining placement capacity under rule 7.1

“A”

Note: number must be same as shown in Step 1 of Part 1

335,297,780 CDIs (assuming all shares of common stock were held as CDIs).

Step 2: Calculate 10% of “A”

“D”

0.10

Multiply “A” by 0.10

33,529,778 CDIs (assuming all shares of common stock were held as CDIs).

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

·                  This applies to equity securities — not just ordinary securities

·                  Include here — if applicable — the securities the subject of the Appendix 3B to which this form is annexed

·                  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

·                  It may be useful to set out issues of securities on different dates as separate line items

Nil

“E”

Nil

“A” x 0.10

Note: number must be same as shown in Step 2

33,529,778 CDIs (assuming all shares of common stock were held as CDIs).

Subtract “E”

Note: number must be same as shown in Step 3

Nil

Total [“A” x 0.10] – “E”

33,529,778 CDIs (assuming all shares of common stock were held as CDIs).

Note: this is the remaining placement capacity under rule 7.1A